Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 4/20 | 0.33 |
| ▸ | PPARA | Q07869 | 4/20 | 0.33 |
| ▸ | LIPE | Q05469 | 2/20 | 0.33 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | GCGR | P47871 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.32 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 2/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6478244 | 0.85 | KCNN3 (0.34) | PPARDPPARALIPEKCNN3PPARG | |
| SCHEMBL4847817 | 0.83 | KCNN3 (0.38) | PPARDPPARALIPEKCNN3PPARG | |
| SCHEMBL14254710 | 0.83 | KCNN3 (0.36) | LIPEKCNN3GCGRMAPTMETAP2 | |
| SCHEMBL4848707 | 0.83 | KCNN3 (0.36) | LIPEKCNN3GCGRMAPTMETAP2 | |
| SCHEMBL4845117 | 0.83 | KCNN3 (0.36) | LIPEKCNN3GCGRMAPTMETAP2 | |
| SCHEMBL14254709 | 0.83 | GRM2 (0.37) | LIPEKCNN3IDH1CYP3A4 | |
| SCHEMBL6485047 | 0.83 | MCHR1 (0.35) | PPARDPPARALIPEKCNN3PPARG | |
| SCHEMBL6477360 | 0.83 | GCGR (0.35) | LIPEKCNN3GCGRIDH1METAP2 | |
| SCHEMBL14254846 | 0.82 | GCGR (0.35) | LIPEKCNN3GCGRCYP2C9IDH1 | |
| SCHEMBL4849155 | 0.81 | SMPD3 (0.38) | PPARDPPARALIPEKCNN3GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342012-B2 | Inhibitors of αLβ2 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2005-07-07 | — | — | US | disclosed |
| US-6897225-B1 | Inhibitors of αLβ2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2005-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | ITGB2, ITGA2B, ITGB1 | CCR5 438/4885PPARD 4167/4885PPARA 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.